Skip to main content
Top
Published in: Supportive Care in Cancer 6/2017

01-06-2017 | Original Article

Urine drug screen findings among ambulatory oncology patients in a supportive care clinic

Authors: Sherri Rauenzahn, Adam Sima, Brian Cassel, Danielle Noreika, Teny Henry Gomez, Lynn Ryan, Carl E. Wolf, Luke Legakis, Egidio Del Fabbro

Published in: Supportive Care in Cancer | Issue 6/2017

Login to get access

Abstract

Purpose

Professional organizations provide no guidelines regarding assessment and management of opioid abuse risk in cancer. Universal precautions (UP) developed for non-cancer pain, include assessments for aberrant behavior, screening questionnaires, and urine drug screens (UDS). The role of UDS for identifying opioid abuse risk in cancer is uncertain. Our aim is to characterize inappropriate UDS, and identify a potential role for UDS in therapeutic decision-making.

Methods

An observational retrospective chart review of 232 consecutive supportive care clinic patients were seen during the study. Twenty-eight of the two hundred thirty-two did not meet inclusion criteria. One hundred fifty of the two hundred four had active cancer, while 54 had no evidence of active disease. Clinicians ordered UDS based on their clinical judgment of patients’ substance misuse risk. Edmonton symptom assessment scores, history of substance abuse, alcohol use, tobacco use, aberrant behavior, and morphine equivalent daily dose (MEDD) were obtained.

Results

Pain scores and MEDD were higher (p = 0.021; p < 0.001) in the UDS group vs non-UDS. Forty percent of the patients (n = 82/204) had at least one UDS and 70% (60/82) had an inappropriate result. Thirty-nine percent (32) were inappropriately negative, showing no prescribed opioids. Forty-nine of the eighty-two were positive for non-prescribed opioids, benzodiazepine, or illicit substance. Eleven of the forty-nine had only cannabis metabolites in their urine. There were no significant differences between appropriate and inappropriate UDS groups regarding pain scores, MEDD or referral to psychology, psychiatry, or substance abuse specialists.

Conclusions

UDS on the 82 oncology patients at high risk for substance misuse were frequently positive (46%) for non-prescribed opioids, benzodiazepines or potent illicit drugs such as heroin or cocaine, and 39% had inappropriately negative UDS, raising concerns for diversion.
Literature
5.
go back to reference Turner JA, Saunders K, Shortreed SM, Rapp SE, Thielke S, LeResche L et al (2014) Chronic opioid therapy risk reduction initiative: impact on urine drug testing rates and results. J Gen Intern Med 29(2):305–311. doi:10.1007/s11606-013-2651-6 CrossRefPubMed Turner JA, Saunders K, Shortreed SM, Rapp SE, Thielke S, LeResche L et al (2014) Chronic opioid therapy risk reduction initiative: impact on urine drug testing rates and results. J Gen Intern Med 29(2):305–311. doi:10.​1007/​s11606-013-2651-6 CrossRefPubMed
12.
go back to reference Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T, Webster L (2014) Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial. Postgrad Med 126(4):20–32. doi:10.3810/pgm.2014.07.2780 CrossRefPubMed Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T, Webster L (2014) Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial. Postgrad Med 126(4):20–32. doi:10.​3810/​pgm.​2014.​07.​2780 CrossRefPubMed
13.
15.
go back to reference Koyyalagunta D, Bruera E, Aigner C, Nusrat H, Driver L, Novy D (2013) Risk stratification of opioid misuse among patients with cancer pain using the SOAPP-SF. Pain Med 14(5):667–675. doi:10.1111/pme.12100 CrossRefPubMed Koyyalagunta D, Bruera E, Aigner C, Nusrat H, Driver L, Novy D (2013) Risk stratification of opioid misuse among patients with cancer pain using the SOAPP-SF. Pain Med 14(5):667–675. doi:10.​1111/​pme.​12100 CrossRefPubMed
18.
go back to reference Paulozzi LJ, Mack KA, Hockenberry JM (2014) Division of Unintentional Injury Prevention NCfIP, Control CDC. Vital signs: variation among States in prescribing of opioid pain relievers and benzodiazepines–United States, 2012. MMWR Morb Mortal Wkly Rep 63(26):563–568PubMed Paulozzi LJ, Mack KA, Hockenberry JM (2014) Division of Unintentional Injury Prevention NCfIP, Control CDC. Vital signs: variation among States in prescribing of opioid pain relievers and benzodiazepines–United States, 2012. MMWR Morb Mortal Wkly Rep 63(26):563–568PubMed
Metadata
Title
Urine drug screen findings among ambulatory oncology patients in a supportive care clinic
Authors
Sherri Rauenzahn
Adam Sima
Brian Cassel
Danielle Noreika
Teny Henry Gomez
Lynn Ryan
Carl E. Wolf
Luke Legakis
Egidio Del Fabbro
Publication date
01-06-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 6/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3575-1

Other articles of this Issue 6/2017

Supportive Care in Cancer 6/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine